NZ546375A - Non-tabletted, chewable, individually dosed administration forms containing stabilising agents that facilitate their removal from packaging - Google Patents

Non-tabletted, chewable, individually dosed administration forms containing stabilising agents that facilitate their removal from packaging

Info

Publication number
NZ546375A
NZ546375A NZ546375A NZ54637504A NZ546375A NZ 546375 A NZ546375 A NZ 546375A NZ 546375 A NZ546375 A NZ 546375A NZ 54637504 A NZ54637504 A NZ 54637504A NZ 546375 A NZ546375 A NZ 546375A
Authority
NZ
New Zealand
Prior art keywords
composition
water
weight
administration form
stabilising agent
Prior art date
Application number
NZ546375A
Other languages
English (en)
Inventor
Vidal Jose Luis Fabregas
Gonzalez Nuria Garcia
Coll Pere Guiro
Carbonell Antoni Masso
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ546375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of NZ546375A publication Critical patent/NZ546375A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ546375A 2003-11-10 2004-11-09 Non-tabletted, chewable, individually dosed administration forms containing stabilising agents that facilitate their removal from packaging NZ546375A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.
PCT/EP2004/012658 WO2005048974A2 (en) 2003-11-10 2004-11-09 Non-tabletted, chewable, individually dosed administration forms

Publications (1)

Publication Number Publication Date
NZ546375A true NZ546375A (en) 2009-11-27

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ546375A NZ546375A (en) 2003-11-10 2004-11-09 Non-tabletted, chewable, individually dosed administration forms containing stabilising agents that facilitate their removal from packaging

Country Status (25)

Country Link
US (1) US20070134318A1 (https=)
EP (1) EP1682097B1 (https=)
JP (1) JP4879021B2 (https=)
KR (1) KR20060116821A (https=)
CN (1) CN1878542A (https=)
AR (1) AR048050A1 (https=)
AT (1) ATE492270T1 (https=)
AU (1) AU2004290517B2 (https=)
BR (1) BRPI0416215A (https=)
CA (1) CA2548615A1 (https=)
CO (1) CO5690531A2 (https=)
DE (1) DE602004030706D1 (https=)
EC (1) ECSP066553A (https=)
ES (2) ES2235626B1 (https=)
IL (1) IL175285A (https=)
MY (1) MY143793A (https=)
NO (1) NO20062723L (https=)
NZ (1) NZ546375A (https=)
PE (1) PE20050488A1 (https=)
RU (1) RU2369379C2 (https=)
TW (1) TW200526266A (https=)
UA (1) UA90253C2 (https=)
UY (1) UY28586A1 (https=)
WO (2) WO2005048975A1 (https=)
ZA (1) ZA200602416B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0716715B1 (pt) 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
CA2670966A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
CN101686942B (zh) * 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
WO2010150261A1 (en) 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
WO2021092439A1 (en) 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
US20070134318A1 (en) 2007-06-14
BRPI0416215A (pt) 2006-12-26
PE20050488A1 (es) 2005-08-24
UY28586A1 (es) 2005-05-31
CN1878542A (zh) 2006-12-13
ATE492270T1 (de) 2011-01-15
MY143793A (en) 2011-07-15
WO2005048974A2 (en) 2005-06-02
ECSP066553A (es) 2006-12-20
ES2235626B1 (es) 2006-11-01
IL175285A (en) 2011-04-28
WO2005048974A3 (en) 2006-02-23
ES2235626A1 (es) 2005-07-01
AU2004290517B2 (en) 2010-05-27
CA2548615A1 (en) 2005-06-02
TW200526266A (en) 2005-08-16
NO20062723L (no) 2006-06-12
ES2358332T3 (es) 2011-05-09
UA90253C2 (ru) 2010-04-26
JP2007510690A (ja) 2007-04-26
EP1682097A2 (en) 2006-07-26
DE602004030706D1 (de) 2011-02-03
AU2004290517A1 (en) 2005-06-02
CO5690531A2 (es) 2006-10-31
RU2369379C2 (ru) 2009-10-10
EP1682097B1 (en) 2010-12-22
KR20060116821A (ko) 2006-11-15
WO2005048975A1 (en) 2005-06-02
IL175285A0 (en) 2006-09-05
ZA200602416B (en) 2009-06-24
RU2006120087A (ru) 2007-12-27
AR048050A1 (es) 2006-03-29
JP4879021B2 (ja) 2012-02-15

Similar Documents

Publication Publication Date Title
EP1682097B1 (en) Non-tabletted, chewable, individually dosed administration forms
US10744103B2 (en) Methods and compositions for treating conditions associated with an abnormal inflammatory responses
ES2651016T3 (es) Formas de dosificación de liberación retardada resistentes a la rotura
CN112955124A (zh) 具有精确的活性物溶出谱的口腔膜组合物和剂型
US10751299B2 (en) Cannabinoid and menthol compositions and methods
AU2016272089B2 (en) Dosage forms and use thereof
JP2017137354A (ja) 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
TW202200121A (zh) 治療方法
CN101919822B (zh) 综合性能改善的片剂及其制备方法
CN109431965A (zh) 药品剂型及其使用
CN115003279A (zh) 前药组合物和治疗方法
EP2528609A1 (en) Propolis and process for the treatment thereof and end products formed therefrom.
US20200069604A1 (en) Cannabinoid and anesthetic compositions and methods
MXPA06005102A (en) Non-tabletted, chewable, individually dosed administration forms
WO2023118074A1 (en) Compressible and free flowing co-processed mesoporous silica
AT500101A1 (de) Verkapselungsprozess
Bngel Preface to the fourth edition
Léber Formulation and investigation of innovative drug delivery systems for the treatment of periodontitis
CA2987114C (en) Method of 3d printing oral dosage forms having a drug in a compartment sealed by an erodible plug

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: LABORATORIOS ALMIRALL, ES

Free format text: OLD OWNER(S): ALMIRALL PRODESFARMA S.A.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)